Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616000569404
Ethics application status
Approved
Date submitted
19/04/2016
Date registered
3/05/2016
Date last updated
24/10/2019
Date data sharing statement initially provided
19/11/2018
Type of registration
Prospectively registered
Titles & IDs
Public title
Randomised study comparing the effects of the stimulant medications dexamphetamine and methylphenidate for treating attention deficit hyperactivity disorder (ADHD)
Query!
Scientific title
Randomised study comparing the effects of the stimulant medications dexamphetamine and methylphenidate for treating attention deficit hyperactivity disorder (ADHD) during initial dose titration
Query!
Secondary ID [1]
289041
0
None
Query!
Universal Trial Number (UTN)
U1111-1182-0982
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Attention Deficit Hyperactivity Disorder
298459
0
Query!
Condition category
Condition code
Mental Health
298559
298559
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Stimulant medication: dexamphetamine (5mg tablet) or methylphenidate (10mg tablet) taken after breakfast and after recess or lunch, with the dose increased weekly as tolerated according to the following schedule
Child weighing less than 25kg: 0.25 tablets twice daily increasing weekly by increments of 0.25 tablets twice daily to maximum of 1 tablet twice daily
Child weighing 25-35kg: 0.5 tablets twice daily the first week, 1 tablet twice daily the second week, 1.5 tablets in the morning and 1 tablet at midday the 3rd week, 1.5 tablets twice daily the 4th week.
Child weighing more than 35kg: 0.5 tablets twice daily increasing weekly by increments of 0.5 tablets twice daily to maximum of 2 tablet twice daily
Query!
Intervention code [1]
294524
0
Treatment: Drugs
Query!
Comparator / control treatment
Comparison of dexamphetamine and methylphenidate; no untreated control group
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
298044
0
Change in symptom scores at school using IOWA Conners Rating Scale
Query!
Assessment method [1]
298044
0
Query!
Timepoint [1]
298044
0
Baseline and weekly during dose titration
Query!
Primary outcome [2]
298045
0
Weight change measured on electronic scales
Query!
Assessment method [2]
298045
0
Query!
Timepoint [2]
298045
0
Baseline and 1 month after starting medication
Query!
Primary outcome [3]
298046
0
Change in cognitive functioning using Stop Signal Task
Query!
Assessment method [3]
298046
0
Query!
Timepoint [3]
298046
0
After titration has established the optimal doses for twice daily administration, the child may attend for one morning and his/her maximum morning dose used in titration will be administered by 3 (for 1.5 tablets) or 4 (for 1 or 2 tablets) half hourly increments, with the Stop Signal Task administered at baseline and half an hour after each increment. This will occur within 18 months of finishing titration.
Query!
Secondary outcome [1]
323008
0
Change in parent quality of life using WHOQOL-BREF
Query!
Assessment method [1]
323008
0
Query!
Timepoint [1]
323008
0
Baseline and 1 month
Query!
Secondary outcome [2]
323170
0
Side effect symptom scale - Barkley
Adverse effects can include insomnia and decreased appetite
Query!
Assessment method [2]
323170
0
Query!
Timepoint [2]
323170
0
Baseline and weekly during dose titration
Query!
Eligibility
Key inclusion criteria
Previously untreated children with ADHD, with or without oppositional defiant disorder
Query!
Minimum age
4
Years
Query!
Query!
Maximum age
17
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Previous treatment with psychotropic medication for ADHD
Child unable to perform computer based cognitive task
Severe psychiatric co-morbidity
Medical contra-indications to stimulant medication
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomised 1:1: 6 permutations randomised using dice-rolling
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
The study relates only to the initial dose titration period; thereafter the medication will be determined by routine clinical means, including discussion with the patient and parent.
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The number required for 90% power that the lower limit of a 2-sided 90% confidence interval (CI) will be above the non-inferiority limit of 1.5 points of improvement on the IOWA Conners Rating Scale is 48 per group. (This assumes a standard deviation of 2.5 points for the change in score). 48 per group will be rounded up to 50 per group.
Statistical analysis using independent samples t-tests for comparing group data and paired t-tests for paired observations. Significant confounders will be controlled for using linear modeling and correlations will use the Pearson correlation.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
4/05/2016
Query!
Actual
24/10/2016
Query!
Date of last participant enrolment
Anticipated
1/06/2020
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2021
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
76
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
5638
0
Nepean Hospital - Kingswood
Query!
Recruitment postcode(s) [1]
13096
0
2750 - Penrith
Query!
Funding & Sponsors
Funding source category [1]
293413
0
Self funded/Unfunded
Query!
Name [1]
293413
0
N/A
Query!
Address [1]
293413
0
N/A
Query!
Country [1]
293413
0
Query!
Primary sponsor type
Government body
Query!
Name
Nepean Blue Mountains Local Health District
Query!
Address
Derby Street
Penrith
NSW 2750
Query!
Country
Australia
Query!
Secondary sponsor category [1]
292256
0
None
Query!
Name [1]
292256
0
Query!
Address [1]
292256
0
Query!
Country [1]
292256
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
294861
0
Nepean Blue Mountains Human Research Ethics Committee
Query!
Ethics committee address [1]
294861
0
The Nepean Hospital
Derby Street
Penrith
NSW 2750
Query!
Ethics committee country [1]
294861
0
Australia
Query!
Date submitted for ethics approval [1]
294861
0
07/08/2015
Query!
Approval date [1]
294861
0
16/11/2015
Query!
Ethics approval number [1]
294861
0
15-37 - HREC15/NEPEAN/80
Query!
Summary
Brief summary
Dexamphetamine and methylphenidate are used in the treatment of attention deficit hyperactivity disorder (ADHD) but few studies directly compare their efficacy. This randomised study has been designed to compare the efficacy and side effects of dexamphetamine and methylphenidate during initial dose titration for treating ADHD. The dose titration schedule will be allocated by weight (maximum dose 1 tablet twice daily for children up to 25kg body weight, 1.5 tablets twice daily for those 25-35kg and 2 tablets twice daily for those weighing more than 35kg: tablets containing 5mg dexamphetamine or 10mg methylphenidate are conventionally considered equipotent). The dose will be increased weekly (as tolerated) over 4 weeks, aiming to establish the lowest dose that gives maximum improvement in functioning. A rating scale will be requested from the child's teacher describing the child's functioning before starting medication and on each dose. Side effects will be monitored with rating scale and measurement of weight and blood pressure. Cognitive functioning using a simple computer-based test will be assessed unmedicated and on each dose used during titration. At the completion of dose titration the participant's active involvement in the study will cease and medication will either be ceased, continued or changed as clinically indicated.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
40490
0
Dr Alison Poulton
Query!
Address
40490
0
Department of Paediatrics
Nepean Hospital
Derby Street
Penrith
NSW 2750
Query!
Country
40490
0
Australia
Query!
Phone
40490
0
+61 47343363
Query!
Fax
40490
0
Query!
Email
40490
0
[email protected]
Query!
Contact person for public queries
Name
40491
0
Dr Alison Poulton
Query!
Address
40491
0
Department of Paediatrics
Nepean Hospital
Derby Street
Penrith
NSW 2750
Query!
Country
40491
0
Australia
Query!
Phone
40491
0
+61 47343363
Query!
Fax
40491
0
Query!
Email
40491
0
[email protected]
Query!
Contact person for scientific queries
Name
40492
0
Dr Alison Poulton
Query!
Address
40492
0
Department of Paediatrics
Nepean Hospital
Derby Street
Penrith
NSW 2750
Query!
Country
40492
0
Australia
Query!
Phone
40492
0
+61 47343363
Query!
Fax
40492
0
Query!
Email
40492
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
This has not been included in the study design or the ethics approval
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF